Journal of Inherited Metabolic Disease

, Volume 25, Issue 7, pp 531–546

Emergency management of inherited metabolic diseases

  • V. Prietsch
  • M. Lindner
  • J. Zschocke
  • W. L. Nyhan
  • G. F. Hoffmann


Inherited metabolic diseases with acute severe manifestations can be divided into five categories: (1) disorders of the intoxication type, (2) disorders with reduced fasting tolerance, (3) disorders with disturbed energy metabolism, (4) disorders of neurotransmission and (5) disorders in which no specific emergency treatment is available. Diagnostic emergency laboratory evaluation should cover all differential diagnoses that are therapeutically relevant and should always include ammonia, glucose, lactate and acid–base status as well as testing the urine for ketones. These are indispensable for planning and conducting the first steps of metabolic emergency treatment and should be available within 30 min. According to the clinical situation and biochemical derangement, special metabolic investigations must be initiated in parallel. These include acylcarnitine profiling with tandem mass spectrometry (in plasma or dried blood spots) and analysis of amino acids in plasma and of organic acids in urine. The results of all laboratory investigations relevant to the diagnosis of metabolic disorders for which specific emergency therapy exists should be available within 24 h. There is general agreement with regard to some therapeutic strategies that are clearly explained by pathophysiology: in disorders with endogenous intoxication, anabolism must be promoted and specific detoxification measures initiated. In disorders with reduced fasting tolerance, administration of glucose at the rate of hepatic glucose production forms the basis of treatment. Correction of acidosis is a major goal in disorders with disturbed mitochondrial energy metabolism, while glucose supply may have to be limited. Many current therapeutic strategies are based on case reports and personal experiences at different metabolic centres. The aim of devising the ‘best’management is often hampered by the lack of objective evidence of efficacy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berry GT, Heidenreich R, Kaplan P, et al (1991) Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease. N Engl J Med 17;324(3): 175-179.Google Scholar
  2. Biggemann B, Zass R, Wendel U (1993) Postoperative metabolic decompensation in maple syrup urine disease is completely prevented by insulin. J Inherit Metab Dis 16: 912-913.Google Scholar
  3. Bodamer OA, Hoffmann GF, Visser GH, et al (1997) Assessment of energy expenditure in metabolic disorders. Eur J Pediatr 156 (Suppl 1): S24-28.Google Scholar
  4. Brown-Harrison MC, Nada MA, Sprecher H, et al (1996) Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 58(1): 59-65.Google Scholar
  5. Chalmers RA, Roe CR, Stacey TE, Hoppel CL (1984) Urinary excretion of l-carnitine and acylcarnitines by patients withdisorders of organic acid metabolism: evidence for secondary insuficiency of l-carnitine. Pediatr Res 18: 1325-1328.Google Scholar
  6. Dixon MA, Leonard JV (1992) Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 67: 1387-1391.Google Scholar
  7. Falk MC, Knight JF, Roy LP, et al (1994) Continuous venovenous haemofiltration in the acute treatment of inborn errors of metabolism. Pediatr Nephrol 8: 330-333.Google Scholar
  8. Feillet F, Leonard JV (1998) Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis 21 (Suppl 1): 101-111.Google Scholar
  9. Feillet F, Bodamer OA, Dixon MA, Sequeira S, Leonard JV (2000) Resting energy expenditure in disorders of propionate metabolism. J Pediatr 136: 659-663.Google Scholar
  10. Fernandes J, Saudubray JM, Van den Berghe G (2000) Inborn Metabolic Diseases, 3rd ed. Berlin: Springer.Google Scholar
  11. Fernhoff PM, Lubitz D, Danner DJ, et al (1985) Thiamine response in maple syrup urine disease. Pediatr Res 19: 1011-1016.Google Scholar
  12. Gebhardt B, Vlaho S, Böhles H (2002) Enhanced ammonia detoxification by N-carbamylglutamate in a patient withdecompensa ted methylmalonic aciduria. 34th European Metabolic Group Meeting, Zürich, 2002, Abstracts, 61.Google Scholar
  13. Green TP, Marchessault RP, Freese DK (1983) Disposition of sodium benzoate in newborn infants with hyperammonemia. J Pediatr 102: 785-790.Google Scholar
  14. Griffith AD, Cyr DM, Egan SG, Tremblay GC (1989) Inhibition of pyruvate carboxylase by sequestration of coenzyme A with sodium benzoate. Arch Biochem Biophys 15;269(1): 201-207.Google Scholar
  15. Hoffmann GF, Nyhan WL, Zschocke J, Kahler SG, Mayatepek E (2002) Inherited Metabolic Diseases. Baltimore: Lippincott Williams and Wilkins.Google Scholar
  16. Hoffmann GF, Prietsch V (2000) Emergency treatment in inborn errors of metabolism. In: Publication of Workshop Results, 32nd European Metabolic Group Meeting, Hamburg, 2000, 22-25.Google Scholar
  17. Jouvet P, Poggi, F, Rabier D, et al (1997) Continuous venovenous haemodiafiltration in the acute phase of neonatal maple syrup urine disease. J Inherit Metab Dis 20: 463-472.Google Scholar
  18. Kalbag SS, Palekar AG (1988) Sodium benzoate inhibits fatty acid oxidation in rat liver: effect on ammonia levels. Biochem Med Metab Biol 40: 133-142.Google Scholar
  19. Kamemoto ES, Atkinson DE (1985) Modulation of the activity of rat liver acetylglutamate synthase by pH and arginine concentration. Arch Biochem Biophys 15;243(1): 100-107.Google Scholar
  20. Marsden D, Barshop BA, Capistrano-Estrada S, et al (1994) Anabolic effect of human growth hormone: management of inherited disorders of catabolic pathways. Biochem Med Metab Biol 52: 145-154.Google Scholar
  21. Matern D, Seydewitz HH, Lehnert W, Niederhoff H, Leititis JU, Brandis M (1996) Primary treatment of propionic acidemia complicated by acute thiamine deficiency. J Pediatr 129: 758-760.Google Scholar
  22. Mayatepek E, Schulze A (1999) Metabolic decompensation and lactic acidosis in propionic acidaemia complicated by thiamine deficiency. J Inherit Metab Dis 22: 189-190.Google Scholar
  23. Mori T, Tsuchiyama A, Nagai K, Nagao M, Oyanagi K, Tsugawa S (1990) A case of carbamylphosphate synthetase-I deficiency associated with secondary carnitine deficiency—L-carnitine treatment of CPS-I deficiency. Eur J Pediatr 149: 272-274.Google Scholar
  24. Morris AA, Leonard JV (1996) The treatment of congenital lactic acidoses. J Inherit Metab Dis 19: 573-580.Google Scholar
  25. Nyhan WL, Ozand PA (1998a) Atlas of Metabolic Diseases. London: Chapman and Hall.Google Scholar
  26. Nyhan WL, Rice-Kelts M, Klein J, Barshop BA (1998b) Treatment of the acute crisis in maple syrup urine disease. Arch Pediatr Adolesc Med 152: 593-598.Google Scholar
  27. Ohtani, Y, Ohyanagi K, Yamamoto S, Matsuda I (1988) Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency. J Pediatr. 112: 409-414.Google Scholar
  28. Parini R, Sereni LP, Bagozzi DC, et al (1993) Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease. Pediatrics 92: 280-283.Google Scholar
  29. Petrowski S, Nyhan WL, Reznik V, et al (1987) Pharmacologic amino acid acylation in the acute hyperammonemia of propionic acidemia. J Neurogenet 4: 87-96.Google Scholar
  30. Potempska A, Loo YH, Wisniewski HM (1984) On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA. J Neurochem 42: 1499-1501.Google Scholar
  31. Prietsch V, Zschocke, J Hoffmann GF (2001) Diagnostik und Therapie des unbekannten Stoffwechselnotfalls. Monatsschr Kinderheilkd 149: 1078-1090Google Scholar
  32. Ring E, Zobel G, Stockler S (1990) Clearance of toxic metabolites during therapy for inborn errors of metabolism. J Pediatr 117: 349-350.Google Scholar
  33. Roe CR, Millington DS, Maltby DA, Bohan TP, Hoppel CL (1984a) L-Carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. J Clin Invest 73: 1785-1788.Google Scholar
  34. Roe CR, Millington DS, Maltby DA, Kahler SG, Bohan TP (1984b) L-Carnitine therapy in isovaleric acidemia. J Clin Invest 74: 2290-2295.Google Scholar
  35. Rutledge SL, Havens PL, Haymond MW, McLean RH, Kan JS, Brusilow SW (1990) Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism. J Pediatr 116: 125-128.Google Scholar
  36. Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E (1999) Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 14: 910-918.Google Scholar
  37. Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. (2001) The Metabolic and Molecular Bases of Inherited Diseases, 8th edn. New York: McGraw-Hill.Google Scholar
  38. Summar M, Pietsch J, Deshpande J, Schulman G (1996) Effective hemodialysis and hemofiltration driven by an extracorporeal membrane oxygenation pump in infants with hyperammonaemia. J Pediatr 128: 379-382.Google Scholar
  39. Thompson GN, Butt WW, Shann FA, et al (1991a) Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism. J Pediatr 118: 879-884.Google Scholar
  40. Thompson GN, Francis DE, Halliday D (1991b) Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management. J Pediatr 119: 35-41.Google Scholar
  41. Walter JH, Wraith JE, Cleary MA (1995) Absence of acidosis in the initial presentation of propionic acidaemia. Arch Dis Child Fetal Neonatal Ed 72(3): F197-199.Google Scholar
  42. Wendel U, Langenbeck U, Lombeck, I Bremer HJ (1982) Maple syrup urine disease—therapeutic use of insulin in catabolic states. Eur J Pediatr 139: 172-175.Google Scholar
  43. Zschocke J, Hoffmann GF (1999) Vademecum Metabolicum. Manual of Metabolic Paediatrics. Stuttgart: Schattauer.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • V. Prietsch
    • 1
  • M. Lindner
    • 1
  • J. Zschocke
    • 3
  • W. L. Nyhan
    • 4
  • G. F. Hoffmann
    • 1
  1. 1.Division of Metabolic and Endocrine DiseasesUniversity Children′s Hospital HeidelbergHeidelberg
  2. 2.Universitäts-KinderklinikHeidelbergGermany
  3. 3.Institute of Human GeneticsUniversity of HeidelbergHeidelbergGermany
  4. 4.Department of PediatricsUniversity of San DiegoCaliforniaUSA

Personalised recommendations